Gene Predictis Overview

  • Founded
  • 2005
Founded
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $497K
Latest Deal Amount
  • Investors
  • 1

Gene Predictis General Information

Description

Developer of precision medicine based on genetics. The company develops precision medicines and other diagnostic tools based on genetics that allow tailored treatments and enables to improve drug treatment efficacy and/or significantly reduce harmful side effects resulting from adverse drug reactions for patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Diagnostic Equipment
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • EPFL Innovation Park
  • PSE-B
  • 1015 Lausanne
  • Switzerland
+41 021 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Gene Predictis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 01-Dec-2015 $497K 00000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Angel (individual) 01-Jan-2005 Completed Startup
To view Gene Predictis’s complete valuation and funding history, request access »

Gene Predictis Patents

Gene Predictis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3046150-A1 Method for predicting the risk of deep vein thrombosis and pulmonary embolism associated with hormonal preparations and hormone levels Pending 09-Dec-2016 0000000000
CA-3046149-A1 Method and kit for predicting the risk of deep vein thrombosis and pulmonary embolism Pending 09-Dec-2016 0000000000
EP-3333267-A1 Method and kit for predicting the risk of deep vein thrombosis and pulmonary embolism Withdrawn 09-Dec-2016 0000000000 0
US-20200071762-A1 Method for predicting the risk of deep vein thrombosis and pulmonary embolism associated with hormonal preparations and hormone levels Pending 09-Dec-2016 0000000000
EP-3551771-A1 Method for predicting the risk of deep vein thrombosis and pulmonary embolism associated with hormonal preparations and hormone levels Pending 09-Dec-2016 C12Q1/6883

Gene Predictis Executive Team (3)

Name Title Board Seat Contact Info
Goranka Tanackovic Ph.D Chief Executive Officer
Joëlle Michaud Ph.D Chief Scientific Officer
Alain Mottaz Ph.D Co-Founder & Board Member
To view Gene Predictis’s complete executive team members history, request access »

Gene Predictis Board Members (4)

Name Representing Role Since
Alain Mottaz Ph.D Gene Predictis Co-Founder & Board Member 000 0000
Frédéric Rochat Self Board Member 000 0000
Sara Mottaz Ph.D Gene Predictis Board Member 000 0000
Thierry Pache MD Gene Predictis Co-Founder & Chairman of the Board of Directors 000 0000
To view Gene Predictis’s complete board members history, request access »

Gene Predictis Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
EPFL Innovation Park Accelerator/Incubator 000 0000 000000 0
To view Gene Predictis’s complete investors history, request access »